Ethoxy acetalated dextran-based nanocarriers accomplish efficient inhibition of leukotriene formation by a novel FLAP antagonist in human leukocytes and blood

• Published in: Cellular and molecular life sciences : CMLS 2022-01, Vol.79 (1), p.40, Article 40
• Main Authors: Kretzer, Christian, Shkodra, Blerina, Klemm, Paul, Jordan, Paul M., Schröder, Daniel, Cinar, Gizem, Vollrath, Antje, Schubert, Stephanie, Nischang, Ivo, Hoeppener, Stephanie, Stumpf, Steffi, Banoglu, Erden, Gladigau, Frederike, Bilancia, Rossella, Rossi, Antonietta, Eggeling, Christian, Neugebauer, Ute, Schubert, Ulrich S., Werz, Oliver
• Format: Article
• Language: English
• Subjects: Animals; Antagonists; Arachidonate 5-lipoxygenase; Benzimidazoles; Biochemistry; Biocompatibility; Biological activity; Biomedical and Life Sciences; Biomedicine; Biosynthesis; Blood; Blood levels; Cell Biology; Centrifuges; Cytotoxicity; Dextran; Dextrans; Dispersion; Drug delivery systems; Encapsulation; Female; Healthy Volunteers; Humans; Inflammation; Intravenous administration; Leukocytes; Leukocytes (neutrophilic); Leukotriene Antagonists - pharmacology; Leukotrienes; Leukotrienes - biosynthesis; Leukotrienes - metabolism; Life Sciences; Light scattering; Lipids; Lipopolysaccharides; Lipoxygenase; Male; Mice; Nanoparticles; Nanoparticles - chemistry; Original; Original Article; Pharmacokinetics; Pharmacology; Photodegradation; Photon correlation spectroscopy; Physicochemical properties; Poly(lactide-co-glycolide); Polylactide-co-glycolide; Raman spectroscopy; Scanning electron microscopy; Scattering; Spectroscopy; Spectrum analysis; Toxicity
• ISSN: 1420-682X; 1420-9071
• DOI: 10.1007/s00018-021-04039-7

Leukotrienes are pro-inflammatory lipid mediators generated by 5-lipoxygenase aided by the 5-lipoxygenase-activating protein (FLAP). BRP-201, a novel benzimidazole-based FLAP antagonist, inhibits leukotriene biosynthesis in isolated leukocytes. However, like other FLAP antagonists, BRP-201 fails to effectively suppress leukotriene formation in blood, which limits its therapeutic value. Here, we describe the encapsulation of BRP-201 into poly(lactide- co -glycolide) (PLGA) and ethoxy acetalated dextran (Ace-DEX) nanoparticles (NPs), aiming to overcome these detrimental pharmacokinetic limitations and to enhance the bioactivity of BRP-201. NPs loaded with BRP-201 were produced via nanoprecipitation and the physicochemical properties of the NPs were analyzed in-depth using dynamic light scattering (size, dispersity, degradation), electrophoretic light scattering (effective charge), NP tracking analysis (size, dispersity), scanning electron microscopy (size and morphology), UV–VIS spectroscopy (drug loading), an analytical ultracentrifuge (drug release, degradation kinetics), and Raman spectroscopy (chemical attributes). Biological assays were performed to study cytotoxicity, cellular uptake, and efficiency of BRP-201-loaded NPs versus free BRP-201 to suppress leukotriene formation in primary human leukocytes and whole blood. Both PLGA- and Ace-DEX-based NPs were significantly more efficient to inhibit leukotriene formation in neutrophils versus free drug. Whole blood experiments revealed that encapsulation of BRP-201 into Ace-DEX NPs strongly increases its potency, especially upon pro-longed (≥ 5 h) incubations and upon lipopolysaccharide-challenge of blood. Finally, intravenous injection of BRP-201-loaded NPs significantly suppressed leukotriene levels in blood of mice in vivo. These results reveal the feasibility of our pharmacological approach using a novel FLAP antagonist encapsulated into Ace-DEX-based NPs with improved efficiency in blood to suppress leukotriene biosynthesis.